Nexalin technology unveils next-generation halo™ clarity

A new neurostimulation device to combat the growing global mental health epidemic designed for drug-free treatment of mental health conditions from the privacy of one's home with virtual monitoring by a physician photo: halo™ clarity headset houston, texas, jan. 11, 2024 (globe newswire) -- nexalin technology, inc. (the “company” or “nexalin”) (nasdaq: nxl; nxliw) today unveiled its gen-3 halo™ clarity 15 milliamp (ma) neurostimulation device designed to treat a variety of mental health conditions, including major depressive disorder (mdd), addiction and substance use disorder, alzheimer's disease, traumatic brain injury (tbi), post-traumatic stress disorder (ptsd), chronic pain and other potentially-applicable stress-related neuropsychiatric disorders. the halo™ clarity utilizes an advanced technique, deep intracranial frequency stimulation (difs™), to penetrate structures deep in the mid-brain that are associated with mental health disorders.
NXL Ratings Summary
NXL Quant Ranking